European Monitoring Centre for Drugs and Drug Addiction
12
World Health Organisation (WHO)
11
IACAPAP
9
et al.
8
Organización Mundial de la Salud OMS
6
Ministry of Health, Rwanda
5
Organisation Mondiale de la Santé OMS
5
WHO
5
Drugs for Neglected Diseases initiative DNDi
4
Indian Council of Medical Research (ICMR)
4
Ministry of Health and Social Services (MOHSS)
4
Ministry of Health, Kenya
4
OPAS
4
Organisation mondiale de la Santé
4
Organisation Mondiale de la Santé OMS
4
Pan American Health Organisation PAHO
4
Pan American Health Organization
4
Africa CDC
3
C. Carandang
3
C. Gray
3
H. Marval-Ospino
3
United Nations Office on Drugs and Crime
3
Wiedenmayer, K. et al.
3
Africa CDC Centres for Disease Control and Prevention
2
Africa Center for Disease Control and Prevention
2
African Union
2
C. Bachmann
2
Centers for Disease Control and Prevention CDC
2
European Union
2
Ministerio de Salud Argentina
2
Ministerio de Salud Chile
2
Ministerio de Salud Pública y Bienestar Social Paraguay
2
Ministry of Health and Sanitation Sierra Leone
2
Ministry of Health, Gabarone, Botswana
2
National Centre for Disease Control (NCDC)
2
National Vector Borne Disease Control Programme (NVBDCP)
2
Organisation de la Santé Mondiale
2
Organización Mundial de Saude and OPAS
2
Pharmacy Board Sierra Leone
2
Republic of Kenya, Ministry of Health
2
Robert-Koch-Institut RKI
2
S. MacPhee
2
T. Lempp
2
United Nations
2
United Nations Office on Drug and Crime UNODC
2
Zambia Medicines Regulatory Authority (ZAMRA)
2
2012
1
2016
1
A. K. Lam
1
A. Martin
1
A. Smajljaj
1
A. Sondheimer
1
A. Sönnerborg
1
A. Xhuvani
1
A.Ramesh
1
Abdulrahim, D.
1
ACCSI, et al.
1
Adrian Sondheimer
1
Agence Japonaise de Cooperation International Kokusai Kogyo Co., Ltd.
1
Agency for Toxic Substances & Disease Registry
1
AIEPI Hospitalario
1
American Chemistry Council
1
and O. Bowden-Jones
1
ANDEMIA
1
Australian National Clinical Evidence Taskforce
1
Berkley, James A.
1
BioNTech
1
Bolivia, Ministerio de Salud, Gobierno de Estado Plurinacional s
1
Bundeszentrale für gesundheitliche Aufklärung
1
Butkus, R. A.
1
Butterworth Heinemann
1
C. Giannou, M. Baldan and A. Molde
1
C. Kalpaki, M. Moudatsou, E. Maraki, et al.
1
Centers for Disease Control and Prevention (CDC)
1
Centre Anti Poison du Maroc
1
Centre d’excellence Africain pour la santé de la Mère et de l’enfant (CEA-SAMEF)
1
Centre for Antibiotic Resistance Research (CARe), University of Gothenburg
1
Chatanga, Peter
1
Chișinău
1
CODEVIDA, Coalición de Organizaciones por el Derecho a la Salud y a la Vida
1
Congressional Research Service
1
Cordner, S.
1
Cureus
1
D. de Lange, D. Radeloff
1
D. Raben
1
D. Radeloff
1
D.de Lange
1
Dadvand, P.
1
Damialis, A.
1
DATER House
1
David P.M., Le Dévédec N. et al.
1
Dermatol Venez, Univerisdad Central de Venezuela
1
Deutsche Hauptstelle für Suchtfragen e.V.
1
Dilys Morgan, Hilary Kirkbride and Bengü Said
1
Directorate General of Health Services Ministry of Health & Family Welfare Government of the People’s Republic of Bangladesh
1
Dr. X. Zeka
1
Drug Safety Monitoring Programme
1
Drugs Advisory Board, Republic of Botswana (Gabarone, Botswana)
1
DTG
1
E. Gjergji
1
E. Subata
1
Elsevier Ltd.
1
EMCDDA
1
et al
1
Europäische Beobachtungsstelle für Drogen und Drogensucht (EMCDDA)
1
European Centre for Disases Prevention and Control ECDC
1
European Scientific Journal
1
F. Fezeu
1
Fairlamb, A.H.
1
Federal Ministries of Agriculture, Environment and Health
1
Food and Agriculture Organization (FAO)
1
Food and Agriculture Organization of the United Nations (FAO), World Health Organization (WHO)
1
Food and Agriculture Organization of the United Nations FAO
1
Food and Drug Authority (FDA), Ghana
1
Food and Drugs Authority (FDA), Ghana
1
Food, Medicine and Health care Administration and Control Authority of Ethiopia (FMHACA)
1
Frewer, A.
1
Friedman, J.F. et al.
1
Fuller, R.
1
Gascon M., Markevych I.
1
GBD 2019 Blindness and Vision Impairment Collaborators
1
GBD 2019 Tuberculosis Collaborators
1
GBD2019 Dementia Forecasting Coolaborators
1
Global smart
1
Gobierno Bolivariano de Venezuela, UNICEF, et al.
1
Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals
1
Government of Kenya
1
Government of South Africa
1
Government of Tanzania
1
Gutiéerrez, J.
1
Gutiérrez, J.
1
H. Furtmayr, K. Krása
1
Haywood, A. and B. D Glass
1
Health Care without Harm
1
Horn, D.
1
Human Rights Watch
1
ICF International
1
ICRC
1
IFRC
1
Indian Council for Medical Research (ICMR)
1
Indian Council of Medical Research (ICMR) & Department of Biotechnology
1
Instituti Shendetit Public
1
International Bureau for Epilepsy
1
International Committee of the Red Cross ICRC
1
International Dairy Federation
1
International Federation of Medical Students’ Associations (IFMSA)
1
International League against Epilepsy
1
International Pharmaceutical Federation FIP
1
Iosue, S.
1
J Pharm Pharm Sci
1
J. M. Rey. M. Irarrázaval
1
J. O. Errecalde
1
J. Sekulić
1
J.-J. Kim
1
Jackson, J., Kheng Heng, L., Eklund, G. et al.
1
Joseph M Rey
1
Kadam. A.
1
Katrin Leitmeyer
1
Kingdom of Swaziland Ministry of Health
1
Koren, H.
1
L'avoisier
1
L. Savikj
1
Laboratorio Central de Salud Publica
1
Liberia Medicines and Health Products Regulatory Authority (LMHRA)
1
Lisa Myers, Laura Theytaz-Bergman
1
M. Hodaj
1
M. Vitoriaa
1
Mapako, Tonderai, Simbarashe Rusakaniko, Maarten J. Postma, Marinus van Hulst, Janet Dzangare, Stellah Ngwende, John Mandisarisa, Ponesai Nyika, David A. Mvere, Owen Mugurungi, and Mufuta Tshimanga
1
Marie-Noel Bruné Drisse and Fiona Goldizen
1
Mario R Dal Poz, Neeru Gupta, Estelle Quain and Agnes LB Soucat
The pre-clinical pipeline shows more innovation and diversity, with 252 agents being developed to treat WHO priority pathogens.
However, these products are in the very early stages of development and still need to be proven effective and safe. The optimistic scenario, the report indicates, is for... the first two to five products to become available in about 10 years.more
The systematic surveillance of antibiotic use and antibiotic re-sistance prevalence in humans and animals is imperative for managingbacterial infectious disease (JPIAMR, 2019;WHO, 2015). Many low-income countries currently face substantial challenges in building national surveillance systems due to ...a lack of infrastructure and resources,resulting in a shortage of systematic data (FAO/OIE/WHO, 2018)more
Antibiotic stewardship refers to coordinated efforts and activities that seek to measure and improve use of antibiotics. Implementation of ASPs has demonstrated positive public health and clinical impacts including reducing costs, lengths of hospital stays, and the burden of antibiotic resistance wh...ile maintaining or improving patient outcomes. The U.S. Centers for Disease Control and Prevention (CDC) released the Core Elements of Hospital Antibiotic Stewardship Programs in 2014, which outlines essential components for ASPs in hospitals and provides practical guidance for implementing a robust ASPin an acute care facility. Variations to the Core Elements have been developed to deal with the particular challenges in small, rural or critical access hospitals in the United States and in outpatient facilities and nursing homes.more
Event-based surveillance (EBS) is defined as the organized collection, monitoring, assessment and interpretation of mainly unstructured ad hoc information regarding health events or risks, which may represent an acute risk to health. Both indicator-based and event-based surveillance components serve... the early warning and response (EWAR) function of the public health surveillance system. The Framework for Event-based Surveillance offers guidance to public health practitioners seeking to implement EBS at each administrative level in their countries.more
Improvements in water sanitation and hygiene (WASH) and wastewater management in all sectors are critical elements of preventing infections and reducing the spread of antimicrobial resistance (AMR) as identified in the Global Action Plan to combat AMR. Yet, at present, WASH and wastewater management... actors and improvement actions are under-represented in AMR multi-stakeholder platforms and national action plans (NAPs). This WHO/FAO/OIE technical brief on WASH and wastewater management to reduce the spread of AMR provides a summary of evidence and rationale for WASH and wastewater actions within AMR NAPs and sector specific policy to combat AMR. Evidence and actions are presented in the domains of; coordination and leadership, households and communities, health care facilities, animal and plant production, manufacturing of antimicrobials, and surveillance and research.more
The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug... Monitoring. This text was developed in consultation with the WHO Collaborating Centre for International Drug Monitoring and the national pharmacovigilance centres participating in the WHO Programme for International Drug Monitoring.more
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir...st issued 8 January 2021, updated 15 June 2021, updated 19 November 2021, updated 21 January 2022, updated 18 August 2022. Available in other languages https://apps.who.int/iris/handle/10665/361720more
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...ed below.
This document has been updated: Version 15 March 2022.more
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat...ed: version 15 March 2022.more
This guidance document provides basic principles for a spokesperson of any health authority on how to respond to vocal vaccine deniers. The suggestions are based on psychological research on persuasion, on research in public health, communication studies and on WHO risk communication guidelines.
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...updated: version 15 March 2022.
The vaccine is formulated from an inactivated SARS-CoV-2 antigen and is presented in single dose vials and multidose vials of 5, 10 and 20 doses.more
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...is document has been updated: version 15 March 2022.more
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Lancet Public health 2022 January 6, 2022 https://doi.org/10.1016/ S2468-2667(21)00249-8
Growth in the number of individuals living with dementia underscores the need for public health planning efforts and policy to address the needs of this group. Country-level estimates can be used to inform nati...onal planning efforts and decisions. Multifaceted approaches, including scaling up interventions to address modifiable risk factors and investing in research on biological mechanisms, will be key in addressing the expected increases in the number of individuals affected by dementia.more